Castle Biosciences Added to Membership of US Small-Cap Russell 2000® Index
September 19 2019 - 7:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer
diagnostics company providing personalized genomic information to
improve cancer treatment decisions, today announced that it will be
added as a member of the US small-cap Russell 2000® Index,
effective after the US market opens on September 23, 2019.
Membership in the Russell 2000® Index, which remains in place for
one year, is based on membership in the broad-market Russell 3000®
Index. The stock also was automatically added to the appropriate
growth and value indexes.
“We are pleased with the company’s inclusion in the Russell
indexes,” said Derek Maetzold, President and CEO of Castle
Biosciences. “This is an important milestone that we believe
reflects the value of our strong organizational execution and the
potential for growth offered by our pipeline of innovative
molecular diagnostic tests addressing skin cancers.”
Russell US Indexes are widely used by investment managers and
institutional investors for passive funds and investment products
and as benchmarks for active investment strategies. Approximately
$9 trillion in assets are benchmarked against Russell US Indexes.
Russell US Indexes are part of FTSE Russell’s suite of index
offerings.
For more information on the Russell US Indexes, go to the FTSE
Russell website.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a commercial-stage
dermatologic cancer company focused on providing physicians and
their patients with personalized, clinically actionable genomic
information to make more accurate treatment decisions. The Company
currently offers tests for patients with cutaneous melanoma
(DecisionDx®-Melanoma, DecisionDx®-CMSeq; www.SkinMelanoma.com) and uveal melanoma
(DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq;
www.MyUvealMelanoma.com), with
products in development for other underserved cancers, the two most
advanced of which are focused on patients with cutaneous squamous
cell carcinoma, and patients who have a difficult-to-diagnose
pigmented lesion. Castle Biosciences is based in Friendswood, Texas
(Houston), and has laboratory operations in Phoenix, Arizona. For
more information, visit www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create ETFs, structured products
and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
Forward-Looking Statements
The information in this press release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the “safe harbor” created by those sections. These forward-looking
statements include, but are not limited to, statements concerning
our execution of our strategic plans and the growth potential
offered by our pipeline products. The words “anticipates,”
“believes,” “estimates,” “expects,” “intends,” “may,” “plans,”
“projects,” “will,” “would” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. We may
not actually achieve the plans, intentions, or expectations
disclosed in our forward-looking statements and you should not
place undue reliance on our forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that we make. These forward-looking statements involve
risks and uncertainties that could cause our actual results to
differ materially from those in the forward-looking statements,
including, without limitation, the risks set forth in our final
prospectus filed with the SEC on July 26, 2019 relating to our
Registration Statements on Form S-1 (File Nos. 333-232369 and
333-232796) and our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2019, filed with the SEC on September 3, 2019, and
in our other filings with the SEC. The forward-looking statements
are applicable only as of the date on which they are made, and we
do not assume any obligation to update any forward-looking
statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190919005198/en/
Frank Stokes, CFO Castle Biosciences, Inc. 866-788-9007
IR@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024